<DOC>
	<DOCNO>NCT00089258</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , monoclonal antibody 3F8 , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Beta-glucan , isotretinoin , sargramostim may increase effectiveness monoclonal antibody 3F8 make tumor cell sensitive monoclonal antibody . Combining different type biological therapy may kill tumor cell . PURPOSE : This phase II trial study well give beta-glucan , isotretinoin , sargramostim together monoclonal antibody 3F8 work treat patient neuroblastoma respond previous treatment .</brief_summary>
	<brief_title>Biological Therapy Treating Patients With Neuroblastoma That Has Not Responded Previous Treatment</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy beta-glucan , isotretinoin , sargramostim ( GM-CSF ) enhance monoclonal antibody 3F8-mediated ablation patient high-risk refractory neuroblastoma . - Determine antitumor activity regimen , term assess disease status bone marrow real-time quantitative reverse transcription polymerase chain reaction , patient . - Determine toxicity regimen patient . OUTLINE : This open-label study . Patients stratify accord refractory disease ( primary refractory [ never disease progression disease recurrence ] v secondary refractory [ recurrent disease respond completely reinduction therapy ] ) . - Courses 1 2 : Patients receive sargramostim ( GM-CSF ) subcutaneously daily day -5 11 . Patients also receive oral beta-glucan daily day -2 11 monoclonal antibody ( MOAB ) 3F8 IV 30-90 minute day 0-4 7-11 . - Courses 3 4 : Patients receive GM-CSF , beta-glucan , MOAB 3F8 . Patients also receive oral isotretinoin twice daily day -2 11 . Treatment repeat every 2-4 week 4 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year . PROJECTED ACCRUAL : A total 27-74 patient ( 10-33 stratum 1 17-41 stratum 2 ) accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroblastoma , define 1 following : Histologically confirm disease Bone marrow metastases plus high urine catecholamine Highrisk disease meet 1 follow stage criterion : Stage IV , 1 following : Any age MYCN amplification &gt; 18 month age without MYCN amplification Stage III , follow : Any age MYCN amplification Unresectable disease Stage 4S MYCN amplification Measurable evaluable soft tissue disease Relapsed disease resistant standard induction chemotherapy salvage therapy PATIENT CHARACTERISTICS : Age Any age Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic No severe hepatic toxicity ≥ grade 3 Renal No severe renal toxicity ≥ grade 3 Cardiovascular No severe cardiac toxicity ≥ grade 3 Pulmonary No severe pulmonary toxicity ≥ grade 3 Other Not pregnant Negative pregnancy test No severe neurologic toxicity ≥ grade 3 No severe gastrointestinal toxicity ≥ grade 3 No severe major organ dysfunction except ototoxicity No history allergy mouse proteins No active lifethreatening infection No human antimouse antibody titer &gt; 1,000 ELISA units/mL PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>